A Phase 1/2a study of WEF-001 in advanced KRAS-mutant solid tumors

Recruiting Phase 1,Phase 2 NCT07148128

Study Description

A research study testing a new cancer drug called WEF-001 in patients with advanced solid tumors that have a specific genetic change called KRAS mutation

Study Details

Registry ID:
NCT07148128
Conditions:
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors, Advanced or Metastatic KRAS-mutant Tumor
Phase:
Phase 1,Phase 2
Target Enrollment:
110 participants
Start Date:
Age Range:
18–999 years
Healthy Volunteers:
No

Study Locations (4 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →